Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: Diabetes meets dermatology

Diabetologia

Volumn 54, Issue 11, 2011, Pages 2741-2744

  Drucker, D J ^a   Rosen, C F ^b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Beta cell; Dipeptidyl peptidase 4; GIP; GLP 1; Immune; Incretin; Inflammation; Skin; T cell

Indexed keywords

ANTIDIABETIC AGENT; ANTIINFLAMMATORY AGENT; ANTIPSORIASIS AGENT; CYCLOSPORIN; CYTOKINE; DERMATOLOGICAL AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ETRETIN; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; IMMUNOMODULATING AGENT; INCRETIN; LIRAGLUTIDE; PIOGLITAZONE; ROSIGLITAZONE; SITAGLIPTIN; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; BULLOUS PEMPHIGOID; CARDIOVASCULAR DISEASE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; LOW DRUG DOSE; NATURAL KILLER CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOTE; NUCLEOTIDE SEQUENCE; OBESITY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PSORIASIS; SYSTEMIC DISEASE; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT REDUCTION;

DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; MALE; NATURAL KILLER T-CELLS; PSORIASIS; RECEPTORS, GLUCAGON;

EID: 80054708816     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-011-2297-z     Document Type: Note

References (21)

1. BB Davidovici N Sattar JC Prinz, et al. 2010 Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions J Invest Dermatol 130 1785 1796 20445552 10.1038/jid.2010.103 1:CAS:528:DC%2BC3cXnsVyitrc%3D
2. Hogan AE, Tobin AM, Ahern T et al (2011) Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells-lessons from obesity, diabetes and psoriasis. Diabetologia. doi: 10.1007/s00125-011-2232-3
3. BP Bullock RS Heller JF Habener 1996 Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide 1 receptor Endocrinology 137 2968 2978 8770921 10.1210/en.137.7.2968 1:CAS:528:DyaK28XjvVWjtLo%3D (Pubitemid 26192194)
4. DJ Drucker 2006 The biology of incretin hormones Cell Metab 3 153 165 16517403 10.1016/j.cmet.2006.01.004 1:CAS:528:DC%2BD28Xislyhtr4%3D
5. I Hadjiyanni KA Siminovitch JS Danska DJ Drucker 2010 Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells Diabetologia 53 730 740 20225396 10.1007/s00125-009-1643-x 1:CAS:528:DC%2BC3cXis1Cmu7s%3D
6. I Hadjiyanni LL Baggio P Poussier DJ Drucker 2008 Exendin-4 modulates diabetes onset in nonobese diabetic mice Endocrinology 149 1338 1349 18063685 10.1210/en.2007-1137 1:CAS:528:DC%2BD1cXisVaqtbw%3D (Pubitemid 351397945)
7. J Zhang Y Tokui K Yamagata, et al. 2007 Continuous stimulation of human glucagon-like peptide-1 (7-36) amide in a mouse model (NOD) delays onset of autoimmune type 1 diabetes Diabetologia 50 1900 1909 17632702 10.1007/s00125-007-0737-6 1:CAS:528:DC%2BD2sXos1Cjt70%3D (Pubitemid 47222856)
8. N Marx M Burgmaier P Heinz, et al. 2010 Glucagon-like peptide-1(1-37) inhibits chemokine-induced migration of human CD4-positive lymphocytes Cell Mol Life Sci 67 3549 3555 20495843 10.1007/s00018-010-0396-5 1:CAS:528: DC%2BC3cXhtFOrtbzO
9. P Libby J Plutzky 2007 Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-α and peroxisome proliferator-activated receptor-γ agonists Am J Cardiol 99 27B 40B 17307056 10.1016/j.amjcard.2006.11.004 1:CAS:528:DC%2BD2sXjsVKms74%3D (Pubitemid 46239949)
10. P Sertznig M Seifert W Tilgen J Reichrath 2008 Peroxisome proliferator-activated receptors (PPARs) and the human skin: importance of PPARs in skin physiology and dermatologic diseases Am J Clin Dermatol 9 15 31 18092840 10.2165/00128071-200809010-00002 (Pubitemid 351993189)
11. MY Donath SE Shoelson 2011 Type 2 diabetes as an inflammatory disease Nat Rev Immunol 11 98 107 21233852 10.1038/nri2925 1:CAS:528:DC%2BC3MXlsFehtQ%3D%3D
12. R Mittal S Malhotra P Pandhi I Kaur S Dogra 2009 Efficacy and safety of combination acitretin and pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: a randomized, double-blind, placebo-controlled clinical trial Arch Dermatol 145 387 393 19380660 10.1001/archdermatol.2009.5 1:CAS:528:DC%2BD1MXlt1GjsLc%3D
13. JF List H He JF Habener 2006 Glucagon-like peptide-1 receptor and proglucagon expression in mouse skin Regul Pept 134 149 157 16631262 10.1016/j.regpep.2006.02.007 1:CAS:528:DC%2BD28XksVClsrg%3D
14. AR Setty G Curhan HK Choi 2007 Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses Health Study II Arch Intern Med 167 1670 1675 17698691 10.1001/archinte.167.15.1670 (Pubitemid 47280349)
15. S Bremmer AS van Voorhees S Hsu, et al. 2010 Obesity and psoriasis: from the Medical Board of the National Psoriasis Foundation J Am Acad Dermatol 63 1058 1069 20692722 10.1016/j.jaad.2009.09.053
16. F Bardazzi R Balestri E Baldi A Antonucci S de Tommaso A Patrizi 2010 Correlation between BMI and PASI in patients affected by moderate to severe psoriasis undergoing biological therapy Dermatol Ther 23 Suppl. 1 S14 19 20136916 10.1111/j.1529-8019.2009.01281.x
17. P Gisondi M del Giglio V Di Francesco M Zamboni G Girolomoni 2008 Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial Am J Clin Nutr 88 1242 1247 18996858 1:CAS:528:DC%2BD1cXhtlOqu73M
18. H Lithell A Bruce IB Gustafsson, et al. 1983 A fasting and vegetarian diet treatment trial on chronic inflammatory disorders Acta Derm Venereol 63 397 403 6197838 1:STN:280:DyaL2c7gtVCmsg%3D%3D
19. I Rucevic A Perl V Barisic-Drusko M Adam-Perl 2003 The role of the low energy diet in psoriasis vulgaris treatment Coll Antropol 27 Suppl. 1 41 48 12955890 (Pubitemid 38340151)
20. DJ Drucker 2007 Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action Diabetes Care 30 1335 1343 17337495 10.2337/dc07-0228 1:CAS:528:DC%2BD2sXntlWksLw%3D (Pubitemid 46871135)
21. Skandalis K, Spirova M, Gaitanis G, Tsartsarakis A, Bassukas I (2011) Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin. J Eur Acad Dermatol Venereol. doi: 10.1111/j.1468-3083.2011.04062.x